Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA
US7118750B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 15, 1998 |
| Grant date | Oct 10, 2006 |
| Priority date | — |
| Expiry date | May 16, 2018 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/144
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A modified human TNFα molecule is capable of raising neutralizing antibodies towards unmodified human TNFα following administration of the modified TNFα to a human host, wherein one or more peptide fragments of the human TNFα molecule has been substituted by one or more peptides containing immunodominant T cell epitopes or a truncated form of the molecule containing the immunodominant epitope and one or both flanking regions of the human TNFα-molecule containing at least one TNFα B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of any one of the strands of the front β-sheet, in any one of the connecting loops, or in any one of the B′, I, or D strands of the back β-sheet.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.